News All News

More than three decades of research by Doug Melton, Catalyst Professor and co-director of the Harvard Stem Cell Institute, led to the launch of Semma Therapeutics and the development of a potential new treatment for Type 1 diabetes that uses stem cells to make healthy insulin-producing cells that can be transplanted into patients. The Blavatnik Biomedical Accelerator supported the research that led to the launch of Semma Therapeutics out of the Melton Lab.

With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

GC Therapeutics (GCTx), a Harvard startup, announced its launch to scale and its technology TFome™, the world’s first “plug and play” induced pluripotent stem cell (iPSC) programming platform for cell therapies in multiple therapeutic areas. 

First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders